Preparation and application of combined subunit vaccine for hemorrhagic disease and septicemia of grass carp
By fusing the genetic technology of grass carp reovirus and Aeromonas Vickers, a double-unit subunit vaccine was prepared, solving the problem that existing vaccines cannot prevent grass carp bleeding and sepsis at the same time, achieving a better protective effect.
Patent Information
- Application Number
- CN202410944666.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-07-10
- Filing Date
- 2024-07-15
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-07-15
AI Technical Summary
The existing vaccines for grass carp hemorrhage and bacterial sepsis cannot effectively prevent and control both epidemics at the same time, and there are problems such as unstable components, high cost, low safety and unsatisfactory cross-protection effect.
Using fusion gene technology, combining the VP6 gene of grass carp reovirus and the ompAII gene of Aeromonas Vickers, expressing the fusion protein, and preparing a bipartite subunit vaccine through recombinant expression vectors and recombinant bacteria, and immunization is carried out in combination with adjuvant. .
The secondary subunit vaccine can effectively stimulate the immune response of fish, significantly improve the protective effect of grass carp hemorrhage and sepsis, and the relative survival rate reaches 85% and 55%, significantly reducing the harm caused by the disease.
Smart Images

Figure BDA0004945271910000021 
Figure BDA0004945271910000031 
Figure BDA0004945271910000041
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to the preparation and application of a bivalent subunit vaccine for grass carp hemorrhagic disease and septicemia. Background Art
[0002] Aquaculture is an important part of agricultural economy. Grass carp is the most important freshwater aquaculture species, and grass carp hemorrhagic disease and bacterial septicemia are the main diseases of aquaculture grass carp.
[0003] The GCRV virus particles of grass carp hemorrhagic disease pathogen mainly include proteins and nucleic acids, contain a small amount of sugars, and do not contain lipids; repeated freezing and thawing has a great influence on the infectivity of the virus. GCRV virus particles are arranged in multiple layers, presenting a regular icosahedral sphere with a diameter of about 55-80nm, without an envelope structure, and the outer capsid is composed of 200 trimers arranged in T=13, and the inner capsid is composed of 120 monomers arranged in T=1. GCRV isolates can be mainly divided into three genotypes, including GCRV-Ⅰ, GCRV-Ⅱ and GCRV-Ⅲ. Due to the differences in genome sequences among strains, the cell culture characteristics, virulence, pathogenicity and antigenicity of each strain are different. The results of epidemiological surveys show that type II strains represented by GCRV HuNan1307 and GCRVGD108 are currently the most prevalent strains causing grass carp hemorrhagic disease.
[0004] Aeromonas veronii is a conditional pathogen that is the main pathogen causing bacterial septicemia in freshwater fish, shrimp, crab, and shellfish, causing symptoms such as decreased immunity, bleeding, ascites, exophthalmos, and enteritis, causing huge economic losses to the aquaculture industry. There are increasing reports of Aeromonas veronii causing bacterial septicemia in freshwater fish. The virulence of Aeromonas veronii is manifested in many aspects, not only related to virulence genes, but also including surface-related molecules, movement, bioactive extracellular products, and biofilm formation.
[0005] Both grass carp reovirus and Aeromonas veronii can cause bleeding and death in grass carp, often accompanied by mixed infection or secondary infection. However, there is currently no effective method to simultaneously prevent and control the occurrence of both diseases.
[0006] Types of existing vaccines and problems they present:
[0007] The grass carp hemorrhagic disease tissue homogenate inactivated vaccine is a traditional vaccine prepared by inactivating the diseased grass carp tissue homogenate. Although it is effective, there are problems with the instability of the vaccine composition and content. In addition, there is the possibility of incomplete inactivation. The above problems make the protection effect of the grass carp hemorrhagic disease tissue homogenate inactivated vaccine unstable, and there is a risk of large-scale outbreaks after use. Although the grass carp hemorrhagic disease cell culture virus inactivated vaccine is safe and reliable, the vaccine cost is high due to the low virus titer, and it is impossible to prepare a multi-component and multivalent vaccine.
[0008] Attenuated vaccines, also known as weakened vaccines or live vaccines, are made from attenuated or non-toxic live pathogenic microorganisms. Compared with inactivated vaccines (dead vaccines), this type of vaccine has strong immunity and long duration of action, but it needs to be frozen for storage and has the potential risk of pathogenicity, excessive irritation and reversion to pathogenicity. According to relevant information, the attenuated vaccine currently approved for use is prepared from the GCRV-I strain, and there is no research and development of attenuated vaccines for GCRV-II. In summary, attenuated live vaccines have low safety and the risk of virulence returning to high levels; and the grass carp hemorrhagic disease live vaccine that has obtained a production batch number has a poor protective effect due to changes in the prevalent strains; Aeromonas vermiformis has multiple serotypes, so the cross-protection effect of the current monovalent grass carp bacterial sepsis attenuated vaccine is also not ideal.
[0009] Genetically engineered subunit vaccines are vaccines prepared by using genetic recombination technology to express and purify antigen protein genes in vitro to obtain vaccines containing only one or several main antigen components. Its advantages are that the antigen components are relatively simple, without virulence factors and other genetic information, will not replicate in the body, are not infectious to the host, and have high safety and stability. At present, many studies have reported on subunit vaccines for grass carp hemorrhagic disease, and good results have been achieved under experimental conditions, but subunit vaccines generally have a low protection rate, and there is currently no multi-component and multivalent vaccine for important grass carp diseases.
[0010] Nucleic acid vaccines use target fragments encoding antigenic proteins to enter the animal body, select their expression system to obtain proteins, induce immune responses and better protective effects. Compared with traditional vaccines, DNA vaccines are relatively simple to prepare, have low production costs, do not require the addition of adjuvants when used, have good stability, high immune efficiency and long duration. However, there are also controversies about the safety of DNA vaccines. For example, DNA is uncontrollable in the body and may be integrated into the host genome, posing risks of genetic and immune tolerance.
[0011] Summary of currently available vaccines:
[0012] Table 1
[0013]
[0014]
[0015]
[0016] Grass carp reovirus and Aeromonas veronii can both cause bleeding and death in grass carp, often accompanied by mixed infection or secondary infection. Prevention is one of the most effective methods for grass carp hemorrhagic disease and septicemia. In addition, immune prevention and control will not cause environmental damage caused by drug prevention and control. Immunization prevention and control is not only safe but also more effective than drug prevention and control. Therefore, the development of effective vaccines has far-reaching significance for the prevention and control of grass carp hemorrhagic disease and leukemia.
[0017] Therefore, in order to effectively control the occurrence of grass carp hemorrhagic disease, the appearance of two pathogens should be controlled at the same time. The present invention uses this as a guide to develop a two-in-one subunit vaccine, so as to achieve multiple preventions with one shot, and jointly control the occurrence of grass carp reovirus and Aeromonas veronii at the same time, thereby reducing the harm caused by grass carp hemorrhagic disease and septicemia. Summary of the invention
[0018] The purpose of the first aspect of the present invention is to provide a fusion gene.
[0019] The second aspect of the present invention aims to provide a fusion protein expressed by the above fusion gene.
[0020] The third aspect of the present invention aims to provide a recombinant expression vector, an expression cassette or a recombinant bacterium comprising the above-mentioned fusion gene or expressing the above-mentioned fusion protein.
[0021] The fourth aspect of the present invention aims to provide applications of the above-mentioned fusion gene, fusion protein, recombinant expression vector, expression cassette or recombinant bacteria.
[0022] The fifth aspect of the present invention aims to provide a product.
[0023] The technical solution adopted by the present invention is:
[0024] In a first aspect, the present invention provides a fusion gene, wherein the fusion gene contains the VP6 gene sequence of grass carp reovirus and the ompAⅡ gene sequence of Aeromonas veronii.
[0025] Preferably, the fusion gene further comprises a linker sequence.
[0026] Preferably, the joint comprises a flexible joint, a rigid joint or a shearable joint.
[0027] Preferably, the sequence of the flexible linker is GGTGGCGGTGGCTCA.
[0028] Preferably, the nucleotide sequence of the fusion gene is as shown in SEQ ID NO.1.
[0029] The second aspect of the present invention provides a fusion protein, wherein the fusion protein is encoded by the fusion gene described in the first aspect of the present invention.
[0030] The third aspect of the present invention provides a recombinant expression vector, an expression cassette or a recombinant bacterium containing the fusion gene as described in the first aspect of the present invention or the fusion protein as described in the second aspect of the present invention.
[0031] Preferably, the expression vector includes but is not limited to pet series, duet series, pgex series, phy300, phy300plk, and ppic series.
[0032] Preferably, the expression vector is a pET32a vector.
[0033] Preferably, the recombinant bacteria include but are not limited to Escherichia coli, Bacillus subtilis, and yeast.
[0034] Preferably, the recombinant bacterium is a recombinant Escherichia coli, classified and named Escherichia coli pET32a-VP6-ompA II / BL21 (Escherichia coli pET32a-VP6-ompA II / BL21), and deposited in the China Type Culture Collection, Wuhan University, Wuhan, China, on May 17, 2024; the deposit number is CCTCC NO: M 2024974.
[0035] The present invention also provides a method for preparing the above fusion protein, comprising the following steps: constructing a recombinant vector containing the encoding of the above fusion gene; transferring the recombinant vector into competent cells, screening positive clones and then culturing, inducing expression, extracting and purifying the protein to obtain the fusion protein.
[0036] The fourth aspect of the present invention provides the use of the fusion gene described in the first aspect of the present invention or the fusion protein described in the second aspect of the present invention or the recombinant expression vector, expression cassette or transgenic recombinant bacteria of the third aspect of the present invention in the preparation of products for preventing and treating diseases caused by grass carp reovirus and / or Aeromonas veronii.
[0037] Preferably, the diseases caused by grass carp reovirus and / or Aeromonas veronii include grass carp hemorrhagic disease and / or grass carp septicemia.
[0038] Preferably, the product further comprises an adjuvant.
[0039] Preferably, the product is a medicine.
[0040] Preferably, the drug is a vaccine.
[0041] Preferably, the vaccine is a subunit vaccine.
[0042] Preferably, the administration routes of the drug include intraperitoneal injection and intramuscular injection.
[0043] Preferably, the adjuvant includes at least one of ISA763A, aluminum hydroxide, lecithin, Freund's adjuvant, MLPTM, IL-12, ISA51VG, ISA720VG, MF59, QS21, and AS03 adjuvants. Those skilled in the art can also select other immune adjuvants for preparing suitable vaccines according to actual use requirements.
[0044] The fifth aspect of the present invention provides a product, which includes the fusion gene described in the first aspect of the present invention or the fusion protein described in the second aspect of the present invention or the recombinant expression vector, expression cassette, transgenic cell line or transgenic recombinant bacteria of the third aspect of the present invention.
[0045] Preferably, the product further comprises an adjuvant.
[0046] Preferably, the product is a medicine.
[0047] Preferably, the drug is a vaccine.
[0048] Preferably, the vaccine is a subunit vaccine.
[0049] Preferably, the administration routes of the drug include intraperitoneal injection and intramuscular injection.
[0050] Preferably, the adjuvant includes at least one of ISA763A, aluminum hydroxide, lecithin, mpltm, il-12, ISA51VG, ISA720VG, MF59, QS21, and AS03 adjuvants. Those skilled in the art can also select other immune adjuvants for preparing vaccines suitable for use according to actual use requirements.
[0051] The present invention also provides a method for preparing the subunit vaccine, comprising mixing the purified fusion protein with an adjuvant.
[0052] Preferably, the mass ratio of the fusion protein to the adjuvant is 1:0.5-2.
[0053] The beneficial effects of the present invention are:
[0054] The invention provides a fusion gene obtained by connecting the VP6 protein of GCRV and the outer membrane protein ompAII of Aeromonas veronii, and the fusion gene is used to express the fusion protein to perform intraperitoneal injection immunization on experimental animals, spleen and kidney tissues are collected, and the expression levels of immune-related genes in various tissues are determined by qPCR; the results show that the prepared two-unit subunit vaccine can stimulate different immune tissues of fish to produce immune response reactions through injection immunization; on the 28th day after immunization, the fish are subjected to a poison challenge experiment by intraperitoneal injection of GCRV strong toxin and Aeromonas veronii, and 15 days after the poison challenge, the relative survival rates (RPS) to Aeromonas veronii and grass carp reovirus infection are 85% and 55% respectively, indicating that the two-unit subunit vaccine of the invention has a good protective effect on important diseases of farmed grass carp. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] Figure 1 : Electrophoresis of VP6-ompAII recombinant gene fragment; Note: M: DNA marker (DL5000); Line 1: VP6-OmpAII.
[0056] Figure 2 : Identification diagram of subcloning vector plasmid; Note: M: DNA marker (DL5000); Line 1: pMD19T-VP6-OmpAII / DH5α plasmid PCR.
[0057] Figure 3 : Enzyme digestion identification diagram of subcloning vector; Note: M: DNA marker (DL10000); Lane 1: BamH I, Xho I digestion; Lane 2: BamH I digestion; Lane 3: Xho I digestion.
[0058] Figure 4 : Cloning vector plasmid identification diagram; Note: M: Marker; Line 1: empty vector; Line 2: pET32a-VP6-OmpAII / DH5α plasmid.
[0059] Figure 5 : Enzyme digestion identification diagram of cloning vector; Note: Line 1: pET32a-VP6-OmpAII / DH5α plasmid; M: Marker; Line 2: BamH I, Xho I digestion; Line 3: BamH I digestion; Line 4: Xho I digestion.
[0060] Figure 6 :VP6 protein expression identification diagram; Note: M: Marker; Line 1: recombinant bacteria; Line 2: empty vector.
[0061] Figure 7:Identification diagram of ompAII protein expression; Note: M: Marker; Line 1: recombinant bacteria; Line 2: empty vector.
[0062] Figure 8 and Fig. 9 :Expression of various immune genes in spleen.
[0063] Fig.10 and Fig.11 :Expression of various immune genes in kidney.
[0064] Fig.12 : Survival rate curve of virus attack. DETAILED DESCRIPTION
[0065] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0066] Experimental animals: Rare Gobius crucianus was donated by the Institute of Hydrobiology, Chinese Academy of Sciences, with a body length of 4±0.5cm.
[0067] Bacteria and strains: Genotype II grass carp reovirus was isolated and preserved by the Aquatic Disease and Immunity Research Laboratory of Pearl River Fisheries Research Institute. The isolation method is: the laboratory uses PSF cells for isolation and culture. The specific method is: the virus is inoculated on a dense monolayer of PSF cells, adsorbed at 28°C for 2 hours, and then the adsorption liquid is discarded and supplemented with M199 culture medium containing 5% fetal bovine serum for culture. The culture is continued at 28°C for 5 to 7 days and the virus is harvested by repeated freezing and thawing. The specific method can be found in "Molecular Epidemiology, Whole Genome Sequence and Prevalent Strain Inactivated Vaccine Research of Grass Carp Reovirus" [D] Zeng Weiwei, South China Agricultural University.
[0068] Main reagents: pET32a vector, Escherichia coli MC1061, Trizol Reagent, PrimeScript TM RTreagent Kit, Takara Bam HI and XhoI restriction enzymes, Takara Ex Genomic DNA extraction kit, Premix Ex TaqTM (Probe qPCR), and Competent Cell Preparation Kit were all purchased from Baoriyi Biotechnology Co., Ltd., SYBR Green Pro Taq HS premixed qPCR was purchased from Aikerui Biotechnology Co., Ltd., LB broth medium was purchased from Beijing Luqiao Technology Co., Ltd., ampicillin was purchased from Beijing Solebold Technology Co., Ltd., IPTG inducer was purchased from Shanghai MacLean Biochemical Technology Co., Ltd., and SDS-PAGE and Western blot related reagents were purchased from Suzhou Xinsaimei Biotechnology Co., Ltd.
[0069] Example 1 Cloning and sequence analysis of VP6 and ompAⅡ genes
[0070] According to the nucleic acid sequence of the VP6 gene of the genotype II GCRV HuNan 1307 strain virus (GenBank accession number KU254575) submitted to NCBI, the upstream and downstream primer sequences were designed, and the VP6 whole gene PCR amplification was performed using the genotype II GCRV HuNan 1307 DNA as a template. The PCR program was: 94°C, 5min; 94°C, 30s, 57°C, 30s, 72°C, 45s, 30cycles; 72°C, 10min.
[0071] The upstream and downstream primer sequences were designed with reference to the primer sequences of Shan Xiaofeng (see Table 1), and the ompAⅡ full gene (GenBank accession number MW110479.1) was PCR amplified using Aeromonas vermifuge GZ09007 DNA as a template. The PCR program was: 94℃, 5min; 94℃, 30s, 57℃, 30s, 72℃, 45s, 30cycles; 72℃, 10min.
[0072] The above two amplified products were cut and recovered, and connected with 19T vector to construct subcloning vector. They were sent to Guangzhou Aiji Biotechnology Co., Ltd. for sequencing. The sequencing results were compared using NCBI Blast online software, and the positive clones with correct comparison results were frozen at -80°C. The nucleic acid sequence was translated into protein sequence using DNAman software, and the protein sequence size was clarified and cluster analysis was performed using Mega software.
[0073] Example 2 Construction of recombinant protein
[0074] The fusion PCR method uses a flexible linker to connect the genotype II grass carp reovirus VP6 gene and the outer membrane protein ompAII gene of Aeromonas vernix. The nucleotide sequence of the flexible linker is: GGTGGCGGTGGCTCA (SEQ ID NO.32). At the same time, Bam HI and XhoI restriction sites are introduced at both ends of the VP6-ompAII gene fragment; the electrophoresis of the VP6-ompAII recombinant gene fragment is shown in Figure 1 .
[0075] The primer sequences are shown in the table below;
[0076] Table 2
[0077] VP6-F GGATCCATGGGTATAGTATCTGAA(SEQ ID NO.2) VP6-R TGAGCCACCGCCACCTCTAGAGTGGTGATGATG(SEQ ID NO.3) ompAII-F GGTGGCGGTGGCTCA ATGAAACTCAAAATG(SEQ ID NO.4) ompAII-R CTCGAGCTGTTGTACTTGCTG(SEQ ID NO.5)
[0078] The coding nucleotide sequence for expressing the VP6-ompAII fusion protein is specifically:
[0079]
[0080] Example 3 Construction of VP6-ompAII recombinant bacteria
[0081] The VP6-ompAII gene fragment was connected to the 19T vector to construct a subcloning vector, and the subcloning vector was transformed into the E. coli competent cell DH5α by heat shock method, and sequenced and identified. The plasmid was extracted from the single colony with the correct sequencing result, and PCR amplification was performed using the 19T-VP6-ompAII / DH5α plasmid as a template and VP6-F and ompAII-R as upstream and downstream primers. The VP6-ompAII gene fragment was purified and recovered by agarose nucleic acid gel electrophoresis and gel recovery. The purified fusion gene VP6-ompAII and the prokaryotic expression vector pET-32a(+) were double-digested, and the plasmid and enzyme digestion identification map of the subcloning vector were respectively detected. Figure 2-3 ; The target fragment and vector were purified and recovered by restriction enzyme ligase, VP6-ompA was connected to the pET32a vector using T4 Ligase ligase, and the ligation product was transformed into Escherichia coli competent cells DH5α to obtain the cloning vector pET32a-VP6-ompAII / DH5α, wherein the plasmid identification and restriction enzyme identification of the cloning vector are shown in Figure 2. Figure 4-5 ; Sequence the cloning vector plasmid, take 0.5 μl of the pET32a-VP6-ompAII / DH5α plasmid with the correct sequencing result and transform it into BL21 competent cells to construct the recombinant bacteria pET32a-VP6-ompAII / BL21 and preserve it for the next experiment.
[0082] Specific:
[0083] 1. Mix 2 μl of VP6-ompAII gene fragment gel recovery product with 1 μl pMD19-T Vector, 2 μl sterile water, and 5 μl Solution I, and react at 16°C for 30 min to connect the VP6-ompAII gene fragment to the 19T vector.
[0084] 2. Add the above full amount system (10 μl) to 100 μl DH5α competent cells, gently pipette to mix, and place on ice for 30 min.
[0085] 3. After heat shock at 42℃ for 90s, quickly transfer to ice and place for 5min.
[0086] 4. Add 890 μl LB resistance-free medium and culture at 37°C and 200r / min for 60 minutes.
[0087] 5. Centrifuge at 12000r / min and discard 800μl supernatant.
[0088] 6. Spread 200 μl of the suspension on LB solid culture medium containing ampicillin, culture at 37°C for 10 h, and observe the colonies.
[0089] 7. Pick a single colony and place it in 15 ml of LB liquid culture medium containing ampicillin, culture it at 37°C and 200r / min for 12 h, send the monoclonal bacterial solution to Aigi Biotech for sequencing. If the sequencing result is correct, extract the plasmid from the monoclonal bacterial solution.
[0090] 8. Using 19T-VP6-OmpAII / DH5α plasmid as template and VP6-F and ompAII-R as upstream and downstream primers, PCR amplification was performed, and the VP6-ompAII gene fragment was purified and recovered by agarose nucleic acid gel electrophoresis and gel recovery.
[0091] 9. Double digest the purified VP6-ompAII fusion gene fragment and the prokaryotic expression vector pET32a(+) with BamHI and XhoI at 37°C for 20 min.
[0092] 10. Purify and recover the target fragment and vector cut by enzyme, and connect the VP6-ompAII fusion gene fragment with the pET32a vector using T4 Ligase ligase at 22°C for 40 minutes to obtain the pET32a-VP6-ompAII recombinant plasmid.
[0093] 11. The pET32a-VP6-ompAII recombinant plasmid was transformed into the competent Escherichia coli DH5α by heat shock method, and a single colony was picked for sequencing.
[0094] 12. Take 0.5 μL of the pET32a-VP6-ompAII / DH5α plasmid with the correct sequencing results and transform it into BL21 competent cells, spread it on LB solid culture medium containing ampicillin resistance, and culture it at 37°C for 10 h to obtain the recombinant bacteria Escherichia coli pET32a-VP6-ompA II / BL21 (Escherichia coli pET32a-VP6-ompA II / BL21), and pick a single colony for seed preservation.
[0095] Example 4 Identification of recombinant protein
[0096] The recombinant bacteria pET32a-VP6-ompAII / BL21 constructed in Example 3 was induced to express using different concentrations of IPTG inducer, and the optimal induction time was explored. After the induction, the samples were crushed and boiled, and protein electrophoresis analysis was performed on 12% SDS-PAGE. After electrophoresis, a part was stained with 0.25% Coomassie Brilliant Blue dye to determine the position of the protein band, and the other part was subjected to immunoblotting analysis.
[0097] Specific:
[0098] 1. Inoculate the recombinant bacteria pET32a-VP6-ompAII / BL21 into LB liquid culture medium at a ratio of 1:100 and culture until the logarithmic growth phase, that is, the OD600 value is between 0.4-0.6.
[0099] 2. Add IPTG inducer at concentrations of 0.2mM / L, 0.4mM / L, 0.6mM / L, 0.8mM / L, and 1mM / L to the bacterial solution and culture at 37°C for 2h, 4h, 6h, 8h, and 10h
[0100] 3. After induction, collect the bacteria by centrifugation at 12000r for 1min, and resuspend and wash the bacteria with PBS.
[0101] 4. Suspend the bacteria in 5 mL of 1×PBS solution and perform ultrasonic disruption with a disruption power of 200 W, working for 2 seconds and resting for 5 seconds, for a total of 15 minutes.
[0102] 5. Collect the crushed precipitate, add SDS gel loading buffer in proportion, mix well and boil for 10 minutes.
[0103] 6. Perform protein electrophoresis analysis on 12% SDS-PAGE, 150V, 40min,
[0104] 7. After electrophoresis, stain with 0.25% Coomassie Brilliant Blue for 2 hours, then discard the staining solution, wash with distilled water several times and add decolorizing solution. Change the staining solution every 1 hour until clear bands appear, and determine the most appropriate inducer concentration based on the thickness of the bands.
[0105] 8. After SDS-PAGE electrophoresis, transfer the proteins on the gel to the NC membrane, block it in 5% skimmed milk powder, and incubate it at 4°C overnight.
[0106] 9. Add PBST (PBS + 0.05% Tween-20) and wash three times, 5 minutes each time.
[0107] 10. Use monoclonal antibodies against VP6 and ompAII proteins as primary antibodies, incubate at 37°C for 2 h, and wash three times.
[0108] 11. Add HRP-labeled goat anti-mouse IgG as secondary antibody, incubate at 37°C for 2 h, and wash 3 times.
[0109] 12. Follow the instructions of the DAB colorimetric kit to develop the color for 1 minute and observe the results.
[0110] The results are as follows Figure 6-7 shown; Figure 6 This is the VP6 protein expression identification diagram. Figure 7This is a diagram for identification of ompAII protein expression.
[0111] Example 5 Application of bivalent subunit vaccine
[0112] The purified protein was fully emulsified with the adjuvant ISA763A in a mass ratio of 1:1 to prepare VP6-ISA763A, ompAII-ISA763A and VP6-ompAII-ISA763A vaccine groups and PBS-ISA763A and PBS control groups. Rare minnows were immunized by intraperitoneal injection and spleen and kidney tissues were collected for quantitative analysis of immune genes 24h, 48h, 72h and 96h after immunization. 28 days after immunization, the GCRV-II HN1307 strain and Aeromonas veronii were challenged respectively, and the mortality of the fish was recorded for 15 consecutive days, and the relative protection rate was calculated.
[0113] Specific:
[0114] 1. The purified proteins VP6, ompAII, Vp6-ompAII and adjuvant ISA763A were mixed and emulsified (volume ratio 1:1) to prepare an oil-in-water emulsion. The final concentrations of VP6, ompAII and Vp6-ompAII were all 1.5 μg / μL.
[0115] 2. 60 test fish were immunized by intraperitoneal injection, with 20 μL injected per fish. 60 test fish in the control group were injected intraperitoneally with 20 μl PBS or PBS-ISA763A per fish.
[0116] 3. At 24h, 48h, 72h, and 96h after immunization, 5 rare crucian carps were randomly selected from each group to collect spleen and kidney, and total RNA of each tissue was extracted and reverse transcribed. β-actin was used as the internal reference gene, and the obtained cDNA was used as a template to determine the relative expression of MHCII, TLR3, TLR5, MyD88, NF-kB, IRF3, IRF7, Mx, IFN-a, IL-8 and IL-1B in each tissue by qRT-PCR. The primer sequence information of each gene is shown in Table 3. The qRT-PCR reaction system is as follows: 10μL 2×SYBR Green TaqHS Premix, 0.4μL of each primer, 0.4μL ROX, 2μL cDNA template and ddH2O added to make up to 20μL, 95℃ pre-denaturation for 5min and then enter the cycle: 95℃, 15s denaturation; 60℃, 45s annealing; a total of 35 cycles. The results were measured using 2 -ΔΔCt Analyze the algorithm.
[0117] Table 3 Primer sequences in fluorescence quantitative PCR
[0118]
[0119] 4. After 4 weeks of immunization, a challenge test was conducted by injecting 20 μL of GCRV-II virus solution and 20 μL of Aeromonas vernix (10LD 50 The mice were fasted for 24 h and 48 h before and after the challenge. Each group was kept in an indoor glass tank at a water temperature of 28±1℃ and observed for 15 days. The mortality rate and relative percentage survival (RPS) were calculated. RPS = (% mortality rate of the control group - % mortality rate of the immune group) / % mortality rate of the control group × 100%.
[0120] Results Figure 8-Figure 12 And Table 4-Table 5:
[0121] Table 4 Protection of the dual subunit vaccine against bacterial sepsis infection
[0122] Group mortality rate Survival rate Relative protection rate PBS 80% 20% -- PBS-ISA763A 53.3% 46.7% 33.4% ompAII-ISA763A 31.3% 68.7% 60.8% VP6-ompAII-ISA763A 12% 88% 85%
[0123] Table 5 Protection of the bivalent subunit vaccine against grass carp hemorrhagic disease infection
[0124] Group mortality rate Survival rate Relative protection rate PBS 86% 14% -- PBS-ISA763A 67.7% 32.3% 21.3% VP6-ISA763AompAII 58.6% 41.4% 31.9% VP6-ompAII-ISA763A 38.7% 61.3% 55%
[0125] The results showed that the prepared bivalent subunit vaccine was able to stimulate different immune tissues of fish to produce immune responses through injection immunization, and the relative survival rates (RPS) against Aeromonas veronii and grass carp reovirus infection were 85% and 55%, respectively, indicating that the bivalent subunit vaccine of the present invention has a good protective effect against important diseases of farmed grass carp.
[0126] The above specific implementations have been described in detail for the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A fusion gene, wherein the fusion gene contains the VP6 gene sequence of grass carp reovirus and the ompAⅡ gene sequence of Aeromonas veronii.
2. The fusion gene according to claim 1, characterized in that The fusion gene further comprises a linker sequence; preferably, the linker comprises a flexible linker, a rigid linker or a cleavable linker.
3. The fusion gene according to claim 1, characterized in that The nucleotide sequence of the fusion gene is shown in SEQ ID NO.
1. 4 . A fusion protein, wherein the fusion protein is encoded by the fusion gene according to any one of claims 1 to 3 .
5. A recombinant expression vector, expression cassette or recombinant bacterium containing the fusion gene according to any one of claims 1 to 3 or the fusion protein according to claim 4.
6. The recombinant bacterium according to claim 5, characterized in that: The recombinant bacteria is a recombinant Escherichia coli; preferably, the classification name of the recombinant Escherichia coli is Escherichia.colipET32a-VP6-ompA II / BL21, and the deposit number is CCTCC NO: M 2024974.
7. Use of the fusion gene described in any one of claims 1 to 3 or the fusion protein described in claim 4 or the recombinant expression vector, expression cassette or recombinant bacteria described in any one of claims 5 to 6 in the preparation of products for preventing and treating diseases caused by grass carp reovirus and / or Aeromonas veronii; preferably, the diseases caused by grass carp reovirus and / or Aeromonas veronii include grass carp hemorrhagic disease and / or grass carp bacterial septicemia.
8. A product, comprising the fusion gene according to any one of claims 1 to 3 or the fusion protein according to claim 4 or the recombinant expression vector, expression cassette or recombinant bacteria according to any one of claims 5 to 6.
9. The use according to claim 7 or the product according to claim 8, characterized in that: The product is a drug; the drug is preferably a vaccine; more preferably a subunit vaccine.
10. The use or product according to claim 9, characterized in that: The vaccine includes an adjuvant; preferably, the adjuvant includes at least one of ISA763A, aluminum hydroxide, lecithin, MLPTM, IL-12, ISA51VG, ISA720VG, MF59, QS21, and AS03 adjuvants; preferably, the administration route of the drug includes intraperitoneal injection and intramuscular injection.
Citation Information
Patent Citations
Recombinant protein coded by GCRV (grass carp reovirus) II type S9 genes and application thereof
CN106866796A
Grass carp reovirus spike VP56 protein subunit vaccine, as well as preparation method and application thereof
CN107823640A
RT-RPA primer, probe, kit and detection method for detecting type II grass carp reovirus (GCRV)
CN112680544A
Construction and application of II type grass carp reovirus VP6 recombinant lactic acid bacteria
CN114908029A
Recombinant lactic acid bacteria for fusion expression of GCRV VP6 and LTB as well as preparation method and application of recombinant lactic acid bacteria
CN116693693A
Cited By
Fusion gene of grass carp NPM1a and II type reovirus VP38, recombinant protein, composition and application
CN120624488A
Large-scale induced fermentation method for recombinant escherichia coli
CN122188899A
